PATIENT CENTRIC MEASURES IN HTAs FOR AUTOIMMUNE DISEASES
|
|
- Aubrey Ramsey
- 5 years ago
- Views:
Transcription
1 PATIENT CENTRIC MEASURES IN HTAs FOR AUTOIMMUNE DISEASES Monday, November 12, 2018 Carlijn Hintzen, Rianne Ernst, Arun Chhikara, Cristina Ivanescu, Anke van Engen, Mary New Copyright 2018 IQVIA. All rights reserved. Autoimmune diseases are mostly chronic, non-fatal and treatment should focus on alleviating symptoms Psoriasis Chronic disease with flares Symptoms include Arthritis Red patches of skin covered with thick scales Small scaling spots (common in children) Dry, cracked skin that may bleed Itching, burning or soreness Thickened, pitted or ridged nails 1 2 Inflammation of one or more joints Main symptoms are joint pain, stiffness others include: Pain Stiffness Swelling Redness Decreased range of motion Systemic lupus erythematosus (lupus) Systemic autoimmune disease with episodes, or flares Most distinctive sign is a facial rash shaped like wings of a butterfly; other symptoms include: Fatigue, fever, joint pain, stiffness and swelling, photosensitivity, Raynaud's phenomenon, shortness of breath, chest pain, dry eyes, headaches, confusion and memory loss Inflammatory bowel disease Ulcerative colitis long-lasting inflammation and sores in the colon and rectum Crohn s disease inflammation of the lining of the digestive tract Symptoms common to both disorders include: (Severe) diarrhea, fever and fatigue, abdominal pain and cramping, blood in your stool, reduced appetite and unintended weight loss Sources:
2 Clinical Outcome Assessments (COAs) are used to measure the patient experience which is important to show treatment benefit Patient Reported Outcome (PRO) A measurement that comes directly from the patient Clinician Reported Outcome (ClinRO) An assessment determined by a trained medical professional Composite Measure (CM) A measurement that integrates two or more individual measures Performance Rated Outcome (PerfO) A measurement based on a task(s) performed by a patient Observer Reported Outcome (ObsRO) An assessment determined by an observer (i.e., a nonclinician, such as a teacher or caregiver). *All definitions are based on the definitions determined by PROQOLID 3 To research the impact of COA use in HTA submissions, submissions for HTA agencies between are analysed Relevant HTA submissions are identified via the use of data from the HTA Accelerator platform. Research scope included: auto-immune diseases: lupus,, arthritis, Crohn s disease, ulcerative colitis HTA agencies: HAS, G-BA, IQWiG, NICE, SMC HTA reports published between To prevent skewed data, the scope was further limited to: Included assessment types: original, resubmission, extension of indication Analysis The 13 submission in scope are analysed on inclusion of COA data in the submission. Analysis included if COA data are submitted, which COA type is submitted, if COA data are accepted by HTA agencies and if we see different trends between the auto-immune diseases
3 All HTA submissions including clinical data include COA data, the submission clinical data differs per disease area % HTA submissions including COA data over time (n=12) Inclusion of COA data per indication (n=113) % 77% % 16 17% 13% 78% % 70% % % 92% % 6% 7% % 97% % 1% 80% 22 9% 86% Arthritis Psoriasis % 6 83% SLE 20% 80% CD UC no data submitted unknown submission of data submission included COA data In >9% the COA was a primary endpoint in the clinical trial To prevent double-counting only assessments by IQWiG are included for each drug. One assessment by G-BA for off-label use of a drug as this was not assessed by IQWiG The percentage of different COA types differs per disease, as different COAs are used for each disease Types of COAs submitted per indication 6% 92% 96% 9% 60% 17% 11% % 0% Arthritis (2) Psoriasis (19) Systemic Lupus Erymathosus (SLE) () 7% 80% 80% 0% 13% 0% 0% Crohn s disease (CD) (8) Ulcerative colitis (UC) () IQVIA HTA Accelerato HTA submission in auto-immune disease for HTA agencies published between 2011 and 2017 [data extraction October 2018] To prevent double-counting only assessments by IQWiG are included for each drug. One assessment by G-BA for off-label use of a drug as this was not assessed by IQWiG 6 3
4 For all disease areas different COAs are used in clinical trials, this is guided by recommendations by regulators Top 3 of submitted COAs #1 COA #2 COA #3 COA EMA guideline compliant Arthritis (2) ACR HAQ DAS-28 Crohn s disease (8) CDAI (Crohn s) IBDQ ~ Psoriasis (19) PASI BSA SLE () BILAG Index SELENA- SLEDAI PhGA Ulcerative colitis () Mayo Score IBDQ EQ-D ~ Composite ClinRO PRO Disease-specific COA Generic COA Compliant ~ measure Historically compliant 7 COA data are used by IQWiG to determine a product s morbidity and HRQoL benefit rating, however not all COA data is evaluated Drug Indication* COA for morbidity Cosentyx Cosentyx resubm Taltz Olumiant Xeljanz Kevzara Kyntheum Active rheumatoid arthritis Rheumatoid arthritis Rheumatoid arthritis PASI; Symptom NRS; EQ-D VAS PASI; NAPSI PASI; Itch NRS; NAPSI; VAS; EQ-D VAS PASI; VAS NAPPA-Clin; EQ-D VAS DAS-28; SDAI; VAS; EQ-D VAS; FACIT-F; HAQ-DI CDAI; SDAI; DAS-28; VAS; FACIT-F; HAQ-DI; MOS Sleep Scale CDAI; SDAI; DAS-28; VAS; EQ-D VAS; FACIT-F; HAQ-DI COA for HRQoL ; ; ; Morbidity rating HRQoL rating Safety IQWiG rating G-BA rating Comments PASI NRS Based on the symptoms data IQWiG concludes a lower rating for patients with previous PASI treatment whilst G-BA concludes a higher rating PASI PASI PASI; VAS Non-PRO CDAI, SDAI, DAS-28, HAQ-DI CDAI, SDAI, DAS-28 CDAI, SDAI, DAS-28 HAQ- DI HAQ- DI VAS VAS PASI; NAPSI; PSI PASI G-BA weighed the no benefit for symptoms and more harm in side effects more than IQWiG IQWiGs addendum changed the rating from lesser benefit to no added benefit IQWiG concluded that no significant differences were seen for all endpoints IQWiGs addendum changed the rating from lesser benefit to no added benefit IQWiG concluded that no significant differences were seen for all endpoints IQWiG split the group dependent on remission being a therapy goal. GB-A did not make this split, therefore they have provided the same rating for both groups. IQWiG benefit rating Major added benefit Considerable added benefit Minor added benefit Non-quantifiable added benefit No added benefit Major more harms or less benefit Considerable more harms Minor more harms Non-quantifiable more harms *All indications are moderate to severe Change after addendum 8 4
5 All analysed agencies use submitted COA data in their HTA decisions, as these instruments are well-known and established The morbidity endpoint category is based on physical status (HAQ-DI), as well as statistically based on low disease activity (SDAI 11) and shows a significant benefit for baricitinib + MTX over the ACT G-BA on Olumiant There is an indication of considerable added benefit for morbidity (remission [PASI 0]). For HRQoL, there was an indication of a minor added benefit of ixekizumab compared to ustekinumab at the outcome "" IQWiG on Taltz Clinical experts explained that there is now a move towards more objective assessment of disease activity. The committee accepted that the use of the CDAI was acceptable given its historic use in assessing response to other biological treatments NICE on Stelara The primary outcome was ACR20 response, which is a validated outcome in rheumatoid arthritis SMC on Inflectra The choice of ACR 20 as the main co-criterion for judging efficacy can be discussed because it represents a very modest objective (improvement of 20% of signs and symptoms in relation to baseline) HAS on Kevzara 9 COA data of which the use is increased over the years, is evaluated by agencies and can be a differentiator for products Frequency of COA data All submissions in scope which submitted data, included COA data as part of the clinical data package In >9% of the submitted clinical trials COA data was the primary endpoint Type of COA data The distribution of COA types used differs per disease but for all diseases the most frequently used COA is either a composite measure or ClinRO, used COAs are in line with the disease guidance from regulators Acceptance of COA data COA instruments are generally accepted as these are well-known, established and disease guidance Recommendations are driven by the significance of the results measures with COAs
6 QUESTIONS 11 6
2. Have your symptoms affected your ability to carry out your daily activities? YES NO
QUESTIONNAIRE Page 1 of 5 Date: Referring MD (Name, Address, Phone Number): Primary Care Physician (Name and Address, Phone Number): Reason for visit: 1. How long have you had symptoms? Describe your symptoms?
More informationOU Children s Physicians Pediatric Arthritis Center
Please complete the following questionnaire for your child: Patient Name: Birth Date: Parent/Caretaker Name: Primary Care Physician (Full Name, City, & State) Mother s Occupation: Fathers Occupation: Name
More informationJUST FOR KIDS SELECTED IMPORTANT SAFETY INFORMATION
JUST FOR KIDS For children ages 6-17 with moderately to severely active Crohn s disease or ulcerative colitis (UC) who haven t responded well to other therapies SELECTED IMPORTANT SAFETY INFORMATION REMICADE
More informationFor the Patient: USMAVNIV
For the Patient: USMAVNIV Other Names: Treatment of Unresectable or Metastatic Melanoma Using Nivolumab U = Undesignated (requires special approval) SM = Skin and Melanoma AV = AdVanced NIV = NIVolumab
More informationDigestion: Small and Large Intestines Pathology
Digestion: Small and Large Intestines Pathology Dr. Ritamarie Loscalzo Medical Disclaimer: The information in this presentation is not intended to replace a one onone relationship with a qualified health
More informationFor the Patient: USMAVPEM
For the Patient: USMAVPEM Other Names: Treatment of Unresectable or Metastatic Melanoma Using Pembrolizumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced PEM = Pembrolizumab
More informationAUTOIMMUNE DISORDERS IN THE ACUTE SETTING
AUTOIMMUNE DISORDERS IN THE ACUTE SETTING Diagnosis and Treatment Goals Aimee Borazanci, MD BNI Neuroimmunology Objectives Give an update on the causes for admission, clinical features, and outcomes of
More informationPatient Reported Outcomes (PROs) in IBD: What Are They and What Does the Clinician Need to Know?
Patient Reported Outcomes (PROs) in IBD: What Are They and What Does the Clinician Need to Know? Peter D.R. Higgins Director, IBD Program University of Michigan What are PROs? ClinRO Patient- Reported
More informationFor the Patient: ULUAVPMB
For the Patient: ULUAVPMB Other Names: Treatment of Advanced Non-Small Cell Lung Cancer Using Pembrolizumab U = Undesignated (requires special approval) LU = LUng AV = AdVanced PMB = PeMBrolizumab ABOUT
More informationMULTI-SYSTEMIC INFECTIOUS DISEASE SYNDROME SYMPTOM QUESTIONNAIRE
MULTI-SYSTEMIC INFECTIOUS DISEASE SYNDROME SYMPTOM QUESTIONNAIRE SECTION 1: SYMPTOM FREQUENCY SCORE Select the frequency of each of the following symptoms. 0 = None 1 = Mild 2 = Moderate 3 = Severe 1.
More informationNivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions
Nivolumab Other Names: Opdivo About this Drug Nivolumab is used to treat cancer. It is given in the vein (IV). Possible Side Effects (More Common) Bone marrow depression. This is a decrease in the number
More informationHorowitz Lyme-MSlDS Questionnaire
Horowitz Lyme-MSlDS Questionnaire The Horowitz Lyme-MSlDS Questionnaire is not intended to replace the advice of your own physician or other medical professional. You should consult a medical professional
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNEOFEN 60 mg suppository
PACKAGE LEAFLET: INFORMATION FOR THE USER NEOFEN 60 mg suppository IBUPROFEN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationLaser Vein Center Thomas Wright MD Page 1 of 4
Demographics Laser Vein Center Thomas Wright MD Page 1 of 4 Patient Name: Address: City, St, Zip Primary Phone: Alternate: DOB: Social Security #: Insurance Information Primary Insurance ID# Group# Subscriber
More informationF A M N O P R S ! D !
A B C D E F A M N O P Q G H I J R S T U V 595 W http://www.encognitive.com/images/digestive-system-2.jpg K L M A N B C O P D E F G D Q R H S I J K http://apbrwww5.apsu.edu/thompsonj/anatomy%20&%20physiology/2020/2020%20exam%20reviews/exam%203/colon%20diagram.jpgd
More informationPast Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1
Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma
More informationArthritis Rheumatism Psoriasis
Arthritis Rheumatism Psoriasis 1 / 6 2 / 6 3 / 6 Arthritis Rheumatism Psoriasis You may think that arthritis is a single condition, but there are many forms of arthritis. Each type can be caused by different
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PART III: PATIENT MEDICATION INFORMATION. ixekizumab
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PART III: PATIENT MEDICATION INFORMATION Pr TALTZ ixekizumab www.lilly.ca Lilly Read this carefully before you start taking TALTZ and each time you
More informationCROHN S DISEASE AND ULCERATIVE COLITIS
Slide 1 CROHN S DISEASE AND ULCERATIVE COLITIS Slide 2 Slide 3 Crohn s Inflammation in the GI tract but usually in the lower part of the small intestines and the colon. Inflammation occur between healthy
More informationLupus. Fast facts. What is lupus? What causes lupus? Who gets lupus?
Lupus Systemic lupus erythematosus, referred to as SLE or lupus, is sometimes called the "great imitator." Why? Because of its wide range of symptoms, people often confuse lupus with other health problems.
More informationCrohn's Disease. What causes Crohn s disease? What are the symptoms?
Crohn's Disease Crohn s disease is an ongoing disorder that causes inflammation of the digestive tract, also referred to as the gastrointestinal (GI) tract. Crohn s disease can affect any area of the GI
More informationDiarrhea may be: Acute (short-term, usually lasting several days), which is usually related to bacterial or viral infections.
Pediatric Gastroenterology Conditions Evaluated and Treated Having a child suffer with abdominal pain, chronic eating problems, or other gastrointestinal disorders can be a very trying time for a parent.
More informationInflectra for Crohn s disease
Inflectra for Crohn s disease Some important information to get you started with your treatment This booklet is intended only for use by patients who have been prescribed Inflectra. Introduction When you
More informationContents. Section 1: Understanding Autoimmune Disorders 2 Autoimmune Information 2 Examples of Autoimmune Disorders 4 Current Statistics 8
Contents Section 1: Understanding Autoimmune Disorders 2 Autoimmune Information 2 Examples of Autoimmune Disorders 4 Current Statistics 8 Section 2: From the Real World to the Lab 10 The Process of Diagnosing
More informationLiving with Lupus: An Insider s Perspective
Living with Lupus: An Insider s Perspective Pamela Thorpe, MD, FACP Lupus Foundation of America, Inc. Philadelphia Tri-State Chapter Volunteer May 2014 My Own Story Is it Lupus Yet? The What What is this?
More informationDefinition Chronic autoimmune disease The body s immune system starts attacking itself Can affect most organs and tissues in the body Brain, lungs, he
LIVING WITH SYSTEMIC LUPUS ERYTHEMATOSUS Stacy Kennedy, M.D.,M.B.A. Rowan Diagnostic Clinic Salisbury, N.C. May 11, 2013 Agenda What is lupus Who is affected Causes of lupus Symptoms and organ involvement
More informationINFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic
INFLAMMATORY BOWEL DISEASE Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic WHAT IS INFLAMMATORY BOWEL DISEASE (IBD)? Chronic inflammation of the intestinal tract Two related
More informationSULFASALAZIN 500mg enteric-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER SULFASALAZIN 500mg enteric-coated tablets SULFASALAZINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a
More informationCertain genes passed on from parent to child increase the risk of developing Crohn's disease, if the right trigger occurs.
Topic Page: Crohn's disease Definition: Crohn's disease from Benders' Dictionary of Nutrition and Food Technology Chronic inflammatory disease of the bowel, commonly the terminal ileum, of unknown aetiology,
More informationDrug Name (specify drug) Quantity Frequency Strength
Prior Authorization Form GEHA FEDERAL - STANDARD OPTION Autoimmune Conditions (FA-PA) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationUNDERSTANDING SYSTEMIC LUPUS ERYTHEMATOSUS
UNDERSTANDING SYSTEMIC LUPUS ERYTHEMATOSUS Stacy Kennedy, M.D.,M.B.A. October 20, 2012 Agenda What is lupus Who is affected Causes of lupus Symptoms and organ involvement Diagnosis Treatment Pregnancy
More informationCROHN S DISEASE. The term "inflammatory bowel disease" includes Crohn's disease and the other related condition called ulcerative colitis.
CROHN S DISEASE What does it consist of? Crohn s disease is an inflammatory process that affects mostly to the intestinal tract, although it can affect any other part of the digestive apparatus from the
More informationCity State Zip Code. Ethnic Background: Caucasian African-American Asian Hispanic Native American. Previous. Hobbies/Leisure activities:,,,
History # UPIN # (Please leave blank) Name: First M.I. Last Address: Street (Apt #) City State Zip Code Phone number: ( ) ( ) Home Business Birth Date: / / Day-Month-Year Gender: M F Marital status: (Maiden
More informationSTRESS AND THE HEALTH OF THE BODY
Slide 1 STRESS AND THE HEALTH OF THE BODY Slide 2 What is Stress It is a physical response that occurs in our body when we are stressed Physiologically, it is a series of actions in the body that are regulated
More informationLaser Vein Center Thomas Wright MD RVT Page 1 of 4
Demographics Laser Vein Center Thomas Wright MD RVT Page 1 of 4 Patient Name: Address: City, St, Zip Primary Phone: Alternate: DOB: Social Security #: Marital Status: Married Single Other Emergency Contact:
More informationThe National Association of Crohn s and Colitis of Trinidad and Tobago CROHN S DISEASE AND ULCERATIVE COLITIS GENERAL PATIENT INFORMATION
The National Association of Crohn s and Colitis of Trinidad and Tobago CROHN S DISEASE AND ULCERATIVE COLITIS GENERAL PATIENT INFORMATION You are reading this pamphlet because you or someone you known
More informationLECOM Health Ophthalmology
Patient Name: Date of Birth: New Patient Questionnaire Your answers will be used by your healthcare provider get an accurate history of your medical conditions and ocular concerns. If you are uncomfortable
More informationPATIENT MEDICAL HISTORY PATIENT INFORMATION
PATIENT MEDICAL HISTORY PATIENT INFORMATION Name: Referred here by: Self Family Friend Doctor Other Health Professional If Doctor, please give name & address: List doctors seen in the last 24 months: Relative(s)
More informationOutline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF
Outline Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic Types of biologic drugs How do they work? How effective are they? Safety/Toxicity concerns with biologics Biologic
More informationNutrient Assessment Chart
Vitamin A Assessment Chart Chicken skin on backs of arms Chronic acne Dry eyes Food allergies Poor night vision Recurrent infections and colds Reduced hair growth in children Ulcers B Vitamins Afternoon
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationRHEUMATOLOGY PATIENT HISTORY FORM
!! RAMOS RHEUMATOLOGY, PC RHEUMATOLOGY PATIENT HISTORY FORM Date: / / NAME: Birthdate: / / Last First M. I. Age: Sex: F M Marital status: Never married Married Divorced Separated Widowed Partnered/significant
More informationPSORIASIS DRUGS IN EUROPE - MARKET ACCESS DECISIONS IN COMPARISION BASED ON THE PRISMACCESS DATABASE
PSORIASIS DRUGS IN EUROPE - MARKET ACCESS DECISIONS IN COMPARISION BASED ON THE PRISMACCESS DATABASE Lutz Vollmer 1,3, Daniel Dröschel 1,4, Bruno de Paz 2, Stefan Walzer 1,5 1 MArS Market Access & Pricing
More informationName: Date: Street Address: Referring Physician: How long have you had your current problem?
3851 Piper Street, Suite U464 Anchorage, AK 99508 p 907.339.4800 f 907.339.4801 New Patient Health Questionnaire Name: Date: Street Address: City: State Zip Sex: Age: Birth Date: Insurance: SS# Home Phone:
More informationCenter for Advanced Wound Care New Patient Questionnaire Page 1 of 6
Center for Advanced Wound Care New Patient Questionnaire Page 1 of 6 These questions are general screening questions designed to identify areas where additional attention may be required. Please bring
More informationRisk Management Plan Etoricoxib film-coated tablets
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Osteoarthritis (OA): OA is a condition in which the cartilage of the joints is broken down. This causes stiffness, pain and leads
More informationPharmacy Management Drug Policy
SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber
More informationABUNDANT HEALTH CHIROPRACTIC New Patient Form PERSONAL INFORMATION. Name: Gender: M F Today's Date: / / Birth Date: / / Age: Social Security #: - -
ABUNDANT HEALTH CHIROPRACTIC New Patient Form PERSONAL INFORMATION Name: Gender: M F Today's Date: / / Birth Date: / / Age: Social Security : - - Home Address: City, State, Zip: Home Phone: ( ) Work Phone:
More informationDiscussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor
Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor TECENTRIQ DISCUSSION SUPPORT What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: A type of bladder
More informationThe information you provide us will greatly help us provide the highest quality and most comprehensive care for you.
Rheumatology (circle location of appointment) 111 Hundertmark Rd. Suite 115N 560 S. Maple St. Suite 400 place patient label here Chaska, MN 55318 Waconia, MN 55387 952-361-2450 952-361-2450 The information
More informationPATIENT HEALTH QUESTIONNAIRE Radiation Oncology
REVIEWED DATE / INITIALS Safety: Yes No Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: Yes No If YES, please list medication allergies:
More informationNew Patient History. Name: DOB: Sex: Date: If yes, give the name of the physician who did your evaluation or ordered your tests:
New Patient History Name: DOB: Sex: Date: Chief Complaint: 1. Give a brief description of the problem you are seeking treatment for today: 2. Have you been evaluated for this problem or had any tests for
More informationustekinumab (Stelara )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationPATIENT HEALTH QUESTIONNAIRE Radiation Oncology
REVIEWED DATE / INITIALS Safety: Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: If YES, please list medication allergies: Do you have
More informationMedical therapies and IBD
Medical therapies and IBD Although there is no cure for IBD, there are many treatment options available. There is no standard treatment for IBD that is effective in all situations or for all patients,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationLiver Health: Do you have liver problems? Yes No If so, please specify:
Medical History General Last Name: First Name: Date of Birth: Age: Contact Number: Are you in good health to the best of your knowledge Medical Information: Please list any physicians you see and their
More informationMethotrexate for inflammatory bowel disease: what you need to know
Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or
More informationSystemic Lupus Erythematosus
A Patient s Guide to Systemic Lupus Erythematosus 2 kidneys. These changes make it impossible for the kidneys to function normally. The inflammation of SLE can be seen in the lining, covering, and muscles
More informationCrohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine
Crohn's disease Crohn's disease is an inflammatory condition of the digestive tract that affects children and adults. Common features of Crohn's disease include mouth sores, diarrhea, abdominal pain, weight
More informationFor the Patient: Rituximab injection Other names: RITUXAN
For the Patient: Rituximab injection Other names: RITUXAN Rituximab (ri tux' i mab) is a drug that is used to treat some types of cancer. It is a monoclonal antibody, a type of protein designed to target
More informationCECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425)
IDENTIFYING INFORMATION PATIENT INFORMATION FORM Patient's Name: DOB: Ethnicity/race: Gender: Primary language if other than English: Address: Phone: Home/ Mobile/ Work Email: Occupation: Marital Status:
More informationScrub In. Lymphocytes are a type of what?
Scrub In Lymphocytes are a type of what? a. WBC s b. RBC s c. Thrombocytes d. Plasma The nurse received an injection for immediate immunity following exposure to a patient with an infectious disease. What
More informationNHC Webinar Series on Clinical Outcome Assessments. Patient-Reported Outcomes and Patient-Centered Outcomes: Is There a Difference?
NHC Webinar Series on Clinical Outcome Assessments Patient-Reported Outcomes and Patient-Centered Outcomes: Is There a Difference? NOVEMBER 7, 2018 Outline Why are we having this webinar? Introduction
More informationCandida Questionnaire: Are your health problems yeast connected?
Candida Questionnaire: Are your health problems yeast connected? The following questionnaire can be given to your clients if you suspect candida is a problem. YES NO Have you taken repeated courses of
More informationREMICADE POWDER FOR INJECTION
REMICADE POWDER FOR INJECTION Infliximab PRODUCT INFORMATION NAME OF THE MEDICINE Infliximab Powder for Injection DESCRIPTION Each vial of REMICADE contains infliximab 100 mg. REMICADE Powder for Injection
More informationNew Patient Specialty Intake Form Department of Surgery
This form contains questions specific to the Department of Surgery. If you are new to Baylor College of Medicine and have not been seen in any of our offices, please be sure to complete our New Patient
More informationIxekizumab (plaque psoriasis)
IQWiG Reports Commission No. A17-07 Ixekizumab (plaque psoriasis) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Ixekizumab
More information+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash -
Review of Systems: 0-1 year old Constitution neg Eyes neg GI neg Neurological neg + Activity Change - + Eye Discharge - + Reflux - + Facial Asymmetry - + Appetite Change - + Eye Redness - + Vomiting -
More informationYour treatment with XELJANZ
Your treatment with XELJANZ (tofacitinib citrate) THIS BROCHURE HAS BEEN PRODUCED FOR PATIENTS WHO HAVE BEEN PRESCRIBED XELJANZ. BEFORE USING XELJANZ, PLEASE REVIEW THE PACKAGE LEAFLET FOR THIS MEDICINAL
More informationBiologic Immunomodulators Prior Authorization with Quantity Limit Program Summary
Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the
More informationNew Patient Medical History Form
New Patient Medical History Form Date: Name: Date of Birth: Address: City: ZIP: Home Phone #: Cell Phone #: Emergency Contact: Relationship: Emergency Contact Phone #: Primary Care Physician: Referring
More informationCapital Health Medical Center - Hopewell NEUROSURGICAL-ONCOLOGY Patient History
Capital Health Medical Center - Hopewell NEUROSURGICAL-ONCOLOGY Patient History Please take a few minutes and complete the following questions before you see the doctors so that we may learn a bit more
More information2.0 Synopsis. Adalimumab DE019 OLE (5-year) Clinical Study Report Amendment 1 R&D/06/095. (For National Authority Use Only)
2.0 Synopsis Abbott Laboratories Name of Study Drug: Humira Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationPhysician initials. Date: / / Birthdate: / / Age: Sex: F M
Arthritis and Rheumatology Clinical Center of Northern Virginia R RHEUMATOLOY PATIENT HISTORY FORM Date: / / NAME: Last First M. I. Birthdate: / / Age: Sex: F M Marital status: Never married Married Divorced
More informationMedication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
More informationFor the Patient: USMAVFIPI
For the Patient: USMAVFIPI Other Names: First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced F =
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion Read this carefully before you start
More informationBiologics for Autoimmune Diseases
Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines
More informationAmarillo Surgical Group Doctor: Date:
Office Visit Information (General Surgery) Amarillo Surgical Group Doctor: Date: Patient s Information Name: Last First Middle Social Security #: Date of Birth: Age Gender: [ Male / Female ] Marital Status:
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET SIMPONI Solution for Injection in a pre-filled syringe Solution for Injection in a pre-filled pen, SmartJect NAME OF MEDICINE SIMPONI Solution for Injection in a pre-filled syringe
More informationCoastal Digestive Diseases, P.C. MA New Pt Ht
Coastal Digestive Diseases, P.C. MA New Pt Ht Interview Form Limited Use Only Estab Pt Wt Name Nickname DOB Address Occupation Social Security # Married Single Email Address: Divorced Widowed Check Contact
More informationWhat do you feel are your child s strengths at this time?
PEDIATRIC MEDICAL QUESTIONNAIRE Our ability to draw effective conclusions about your present state of health and how to improve it depends, to a significant extent, on your ability to respond thoughtfully
More informationLife shouldn't take a back seat to plaque psoriasis.
Life shouldn't take a back seat to plaque psoriasis. Journey toward clearer skin with SILIQ. Ask your healthcare provider if SILIQ is an option for you. What is SILIQ? SILIQ injection is a prescription
More informationDo you think you have Lyme Disease? Fill out The Horowitz MSIDS Questionnaire (HMQ)
Do you think you have Lyme Disease? Fill out The Horowitz MSIDS Questionnaire (HMQ) Answer the following questions as honestly as possible. Think about how you have been feeling over the previous month
More informationEli Lilly and Company
Eli Lilly and Company Ixekizumab Phase 2 Psoriasis Data Investment Community Discussion April 10, 2012 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More informationCandida stool test What is Candida? What causes Candida? What are the symptoms of Candida? Why take the test?
Candida stool test What is Candida? Candida albicans can exist in a benign form in various parts of the body the skin, genitals and especially the digestive tract. It is an integral part of our body ecology.
More informationNew Patient Documentation. Name: (Last) (First) (Middle) Address: (Street) (Apt#) (City) (State) (Zip) Home Phone: ( ) Cell: ( ) Work: ( )
New Patient Documentation Name: (Last) (First) (Middle) Address: (Street) (Apt#) (City) (State) (Zip) Home Phone: ( ) Cell: ( ) Work: ( ) Age: Birthdate: E Email: Social: Sex: Male Female Height: Weight:
More informationNew Patient Information Form
New Patient Information Form Patient Label Dear Patient: Please take a few minutes to complete this form. Your answers will help the doctors and staff plan and provide your care. If you are unsure of any
More informationSymptom Questionnaire
Symptom Questionnaire The following questionnaire is a general assessment of your health developed by Dr Royal Lee D.D.S. Each grouping represents a particular area of your body that may be causing you
More informationTrastuzumab (Herceptin )
Trastuzumab (Herceptin ) About This Drug Trastuzumab is used to treat cancer. It is given in the vein (IV) Possible Side Effects Bone marrow depression. This is a decrease in the number of white blood
More informationRegulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio
More information5 Fluorouracil. Other Names: Adrucil. About This Drug. Possible Side Effects. Fluorouracil is used to treat cancer.it is given in the vein (IV).
5 Fluorouracil Other Names: Adrucil About This Drug Fluorouracil is used to treat cancer.it is given in the vein (IV). Possible Side Effects Hair loss. Hair loss is often temporary, although with certain
More informationITS MATCH MAY HAVE MET YOUR METASTATIC COLORECTAL CANCER. Important Safety Information. Indication and Limitation of Use. Your Doctor Discussion Guide
YOUR METASTATIC COLORECTAL CANCER MAY HAVE MET ITS MATCH There are different types of metastatic colorectal cancer (mcrc). If a RAS test shows your mcrc is wild-type RAS, Vectibix may help you live longer.
More informationWhat is ulcerative colitis?
What is ulcerative colitis? Ulcerative colitis is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. Ulcers form where inflammation has killed the cells
More informationNORTHERN VIRGINIA PULMONARY AND CRITICAL CARE ASSOCIATES, P.C.
NORTHERN VIRGINIA PULMONARY AND CRITICAL CARE ASSOCIATES, P.C. Past Medical History AIDS/HIV disease Anemia Asthma Bronchitis Cancer Date of last Chest X-ray Diabetes Mellitus, Type I Diabetes Mellitus,
More informationWHAT IS ULCERATIVE COLITIS?
235 60th Street, West New York, NJ 07093 T: (201) 854-4646 F: (201) 854-4647 810 Main Street, Hackensack, NJ 07601 T: (201) 488-0095 Ulcerative Colitis WHAT IS ULCERATIVE COLITIS? Ulcerative colitis is
More information